The 'Not-Big-Three' Healthcare REITs Just Got More Interesting
Mizuho Securities analyst Richard Anderson recently took a close look at the three senior housing/skilled nursing healthcare REITs under the firm’s coverage: LTC Properties Inc (NYSE: LTC), National Health Investors Inc (NYSE: NHI) and Sabra Health Care REIT Inc (NASDAQ: SBRA).
According to Anderson, once markets stabilize a bit from the recent volatility, the stage could be set for consolidation in the healthcare REIT world.
Anderson sees Sabra as the REIT with the most upside from current levels. He noted the REIT’s valuation discount and experienced management as two key advantages.
In the past, National Health Investors was perceived to be the “darling” of the bunch, but Anderson believes that the departure of CEO Justin Hutchens has opened the door for a new gold standard.
He now sees LTC as the REIT with the “pristine” balance sheet and the consistent record of performance and smart acquisitions. However, while Anderson deems LTC as the most stable of the three names, he noted that its valuation premium limits its upside from current levels.
Anderson believes that the table may be set for consolidation among the three REITs mentioned above and the three REITs not covered by Mizuho: Care Capital Properties Inc (NYSE: CCP), Omega Healthcare Investors Inc (NYSE: OHI) and Senior Housing Properties Trust (NYSE: SNH).
He sees the recent merger of Omega and Aviv and the spinoff of Care Capital creating a very crowded environment in the senior housing REIT space.
“This comment is not intended to make specific M&A predictions, but it seems to us that six relevant REITs in the senior housing/skilled space is possibly one or two too many,” he explained.
In the report, Mizuho upgrades Sabra from Neutral to Buy with a $29 price target. The firm has a Neutral rating and $44 target for LTC and a Neutral rating and $59 target for National Health Investors.
Latest Ratings for LTC
|Jan 2017||Mitsubishi UFJ||Downgrades||Overweight||Neutral|
|Aug 2016||Canaccord Genuity||Maintains||Buy|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.